<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Primary gastrointestinal <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PGL</z:e>) is known to account for 40% of <z:hpo ids='HP_0000001'>all</z:hpo> extranodal non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (NHLs) and between 4% to 12% of <z:hpo ids='HP_0000001'>all</z:hpo> NHLs </plain></SENT>
<SENT sid="1" pm="."><plain>The small intestine is the site of presentation in 20-30% of cases, with the terminal ileum usually involved </plain></SENT>
<SENT sid="2" pm="."><plain>Duodenal localizations have always been thought to be rare, but are presently growing in incidence </plain></SENT>
<SENT sid="3" pm="."><plain>We herein report on a case of Stage IV primary duodenal FCL, located to the second portion of the duodenum with concomitant minimal bone marrow involvement </plain></SENT>
<SENT sid="4" pm="."><plain>The patient was frontline approached with a conservative combined modality treatment consisting of 4 weekly infusions of the chimeric human-murine IgG1 mono-clonal antibody against the B-cell surface antigen CD-20, Rituximab (375 mg/m2) and consolidation 3D conformal external beam radiotherapy up to a total dose of 36 Gy given into 20 fractions to the involved duodenal portion </plain></SENT>
<SENT sid="5" pm="."><plain>Six years after treatment has been completed, the patient is free from disease with no treatment-related toxicity </plain></SENT>
</text></document>